Klotho Neurosciences (KLTO) said Tuesday it is collaborating with AAVnerGene on adeno-associated virus manufacturing and targeted tissue delivery for its therapies to treat Alzheimer's, Parkinson's, ALS, and other conditions.
The collaboration will concentrate on producing KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and other motor neuron disorders, and KLTO-303 for aging-related conditions, the company said.
"The two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes," said Klotho CEO Joseph Sinkule.
Financial terms of the collaboration were not disclosed.
Price: 1.19, Change: -0.01, Percent Change: -0.83
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。